MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)
Status:
Completed
Trial end date:
2018-12-21
Target enrollment:
Participant gender:
Summary
This study, designed as a proof of concept study of MCS110 in pigmented villonodular
synovitis, assessed the clinical response to MCS110 treatment in Pigmented Villonodular
Synovitis (PVNS) patients, after a single or multiple intravenous doses of MCS110, using
magnetic resonance imaging to assess tumor volume, and evaluated the
pharmacokinetics/pharmacodynamics, safety and tolerability in this population.